Quick Facts: Uses of Цефтриаксон ДС

• Treats: Confirmed bacterial infections in various body systems.
• Domains: Respiratory, skin, joints, urinary tract, and central nervous system infections.
• Function: Administered for systemic infections caused by susceptible organisms.

---

Цефтриаксон ДС is indicated for the management of established infections caused by specific, susceptible bacterial strains. Its therapeutic application includes addressing a spectrum of conditions across different organ systems.

The medication is used to provide treatment for certain lower respiratory tract infections, such as pneumonia, where bacterial presence is confirmed. It is also administered to address bacterial infections of the skin and soft tissues, which may present in various clinical scenarios. Additionally, it is a treatment consideration for certain complicated and uncomplicated urinary tract infections (UTIs).

Other areas of use include managing pelvic inflammatory disease (PID), bone and joint infections, and intra-abdominal infections, subject to susceptibility of the causative bacteria. For serious systemic involvement, the medication is employed in the treatment of bacterial septicemia (bloodstream infection) and meningitis (infection of the membranes around the brain and spinal cord). A further, specific use is in surgical prophylaxis, where a single dose may be administered prior to certain procedures to contribute to the reduction of postoperative infection risk.

Цефтриаксон ДС (Ceftriaxone) eligibility is defined by strict regulatory criteria, focusing on patient allergies, age, and organ function. The medicine is contraindicated in specific populations to prevent serious health risks.

Populations Who Must Not Use Ceftriaxone

The medicine is strictly prohibited for patients with a known hypersensitivity to ceftriaxone or any other cephalosporin antibiotic. Absolute contraindications also apply to premature neonates (up to a postmenstrual age of 41 weeks) and hyperbilirubinemic newborns (due to the risk of bilirubin displacement). Furthermore, it is strictly forbidden for neonates (le 28 days) who require or are expected to receive any intravenous calcium-containing solutions.

Age and Condition-Based Restrictions

Use is restricted and requires caution in patients with a history of severe allergy to other beta-lactam drugs, such as penicillin. While generally approved for children, adolescents, adults, and older people, the drug requires careful monitoring and potential dosage limitation for patients with combined severe renal and severe hepatic dysfunction. No automatic dosage adjustment is necessary for patients with isolated severe renal or hepatic impairment.

Interactions with other medicines and products — official regulatory information for Ceftriaxone DS

The official regulatory profile for Ceftriaxone DS defines specific interactions based on physical and pharmacodynamic constraints. The most critical restriction is the formal contraindication of co-administration with intravenous calcium-containing solutions in neonates (≤ 28 days of age), due to the documented risk of potentially fatal precipitation. This precipitation risk is a physical incompatibility that prohibits simultaneous administration in any patient, regardless of age. For patients older than 28 days, administration of the two must be sequential, requiring thorough flushing of the IV line between the infusions.

---

Documented Pharmacodynamic Outcomes and Restrictions

Ceftriaxone DS may cause a potentiated anticoagulant effect when co-administered with oral anticoagulants (e.g., Warfarin), a risk officially described as increasing the likelihood of bleeding. Additionally, co-administration with other substances that affect the kidneys, such as Aminoglycosides or Loop Diuretics, carries a documented increased risk of nephrotoxicity. The drug is also physically incompatible with several solutions, including those containing Aminoglycosides, Vancomycin, Amsacrine, and Fluconazole, requiring strict separation protocols for administration.

The action of Ceftriaxone is strictly bactericidal, meaning its mechanism actively causes the destruction of target bacteria. This effect is mediated through the inhibition of critical bacterial enzymes required for cell wall integrity.

1. Irreversible Inhibition of Cell Wall Assembly

Ceftriaxone functions as an irreversible covalent inhibitor of bacterial enzymes known as Penicillin-Binding Proteins (PBPs), primarily the transpeptidases. The drug permanently binds to and inactivates these enzymes, blocking the final, essential step of peptidoglycan cross-linking necessary to construct a rigid bacterial cell wall. This structural failure leads to the activation of bacterial autolytic enzymes, resulting in lysis (rupture) and cellular destruction.

2. Structural Stability Against Enzymatic Defenses

Ceftriaxone's molecular structure provides stability against certain bacterial defense mechanisms, specifically the beta-lactamase enzymes. This structural property allows the molecule to remain intact and reach its PBP target at concentrations sufficient to support the full inhibitory activity of the mechanism, thereby modulating the progression of the microbial proliferation process.

Цефтриаксон ДС is an injectable medication intended exclusively for parenteral administration, meaning it must be given as an Intravenous (IV) infusion, a slow IV injection, or an Intramuscular (IM) injection. The typical adult dosing regimen involves administering 1 g to 2 g of Ceftriaxone once daily. In cases of severe infection, the dosage may be increased up to a maximum of 4 g per day, which may be administered as two equally divided doses.

---

The sterile powder form requires mandatory reconstitution with a specific diluent before use. A crucial procedural rule is that if the solution is prepared using Lidocaine 1% solution, the route is strictly limited to IM injection only and must never be used intravenously. For high IM doses greater than 1 g, the injection volume must be divided across multiple sites.

---

The medication must not be co-administered simultaneously with any calcium-containing solution, such as Lactated Ringer's or Hartmann's solution, through the same IV line. IV infusions must be administered over a period of at least 30 minutes to ensure correct delivery. Dosing adjustments are specifically required for patients with combined renal and hepatic impairment, where the daily dose should not exceed 2 g. The course of use is commonly 4 to 14 days, often dictated by continuing the regimen for 48 to 72 hours after the infection criteria are met.

Evidence for Use in Lower Respiratory Tract Infections and Pneumonia

Research exploring Ceftriaxone DS for conditions like Community-Acquired Pneumonia (CAP) includes short-term Randomized Controlled Trials (RCTs) and systematic reviews synthesizing these trials. The studies examined measurable outcomes such as the clinical cure rate and microbiological eradication in hospitalized adults and pediatric patients. For critically ill groups, research was associated with measuring serious outcomes like 30-day mortality. Long-term effects are not well characterized, and findings exploring optimal dosing schedules across different patient groups have been mixed.

---

Evidence for Use in Bloodstream and Systemic Infections

Research on bacterial septicemia, or Bloodstream Infections (BSI), was evaluated in retrospective cohort studies and systematic reviews. These studies examined outcomes monitoring physiological strain, including 30-day and 90-day mortality rates, and the frequency of hospital readmission related to treatment failure. The evidence for BSI is largely observational, which limits the certainty of conclusions about cause and effect. Subgroup findings are uncertain, as data for certain pathogen groups remain insufficient.

---

Research on Infection Prevention and Specific Sites

Research for Surgical Prophylaxis is supported by meta-analyses of RCTs that examined the frequency of surgical site infection (SSI) compared to other antibiotics. For Bacterial Meningitis, evidence relies on clinical trials and specialized pharmacokinetic (PK) studies that describe drug concentrations in the Cerebrospinal Fluid (CSF). Data for certain groups remain insufficient, particularly for long-term outcomes, and evidence quality varies across studies when examining the drug in complex or less-studied patient groups.

Key Studies & References

1. WHO Model List of Essential Medicines - Ceftriaxone

Common questions about Цефтриаксон ДС (FAQ)

---

Q: Is there any information on whether Цефтриаксон ДС (Ceftriaxone) can cause candidiasis (thrush)?

Official documents note uncommon reports of candidiasis (a fungal infection) and vaginitis associated with Ceftriaxone use. This is documented in the adverse reactions profile, consistent with how broad-spectrum antibiotics may affect the body's microbial flora.

---

Q: Does Цефтриаксон ДС (Ceftriaxone) affect the effectiveness of hormonal contraceptives?

Official information indicates that, similar to other antibiotics, Ceftriaxone may reduce the effectiveness of hormonal contraceptives (birth control pills). The potential for this interaction is included in the official product information.

---

Q: Is it safe to consume alcohol during treatment with Цефтриаксон ДС (Ceftriaxone)?

Official safety data for Ceftriaxone does not describe the severe disulfiram-like reaction seen with some other antibiotics. However, official information describes the potential for side effects such as dizziness to be enhanced. Information regarding general alcohol consumption during infection is outside the scope of the drug's regulatory safety label.

---

Q: Why is Цефтриаксон ДС (Ceftriaxone) sometimes prescribed in combination with other antibiotics, such as Azithromycin?

Official guidelines state that Ceftriaxone may be co-administered with other antibacterials when the likely range of disease-causing organisms is not fully covered by its own spectrum of activity. This approach is used to ensure comprehensive treatment, for example, to provide additional coverage against specific anaerobic bacteria.

---

Q: What is known about the risk of bacteria developing resistance to Цефтриаксон ДС (Ceftriaxone)?

Bacterial resistance is a documented risk for Ceftriaxone, as it is for all antibiotic classes. This includes known defense mechanisms such as the ability of bacteria to destroy the drug using beta-lactamase enzymes. This is why the medication is recommended for use only when there is a demonstrated, specific need.

---

Q: What are the official recommendations for using Цефтриаксон ДС (Ceftriaxone) during pregnancy?

Official documents state that Ceftriaxone crosses the placental barrier. Use during pregnancy is subject to a careful risk-benefit assessment based on clinical necessity, as described in regulatory documents. Specific documents may note a contraindication for intramuscular injection during this period.

---

Q: Is it permitted to use Цефтриаксон ДС (Ceftriaxone) while breastfeeding?

Official sources confirm that Ceftriaxone is excreted into breast milk at low concentrations. The potential for the drug to affect the infant’s gut flora is noted, which is a factor in determining use during lactation. Some official documents state that intramuscular administration is contraindicated during breastfeeding.

---

Q: Does Цефтриаксон ДС (Ceftriaxone) affect the ability to drive or operate complex machinery?

Official information notes that Ceftriaxone administration can cause side effects such as dizziness. Official information describes the potential for this effect, which may need to be considered when operating vehicles or machinery.

---

Q: Is there evidence that Цефтриаксон ДС (Ceftriaxone) is effective for treating Lyme borreliosis?

The official therapeutic indications for Ceftriaxone include the treatment of disseminated Lyme borreliosis. This covers both early (Stage II) and late (Stage III) stages of the disease.

---

Q: Is it known which specific metabolites of Цефтриаксон ДС (Ceftriaxone) are excreted by the body?

According to official pharmacokinetic data, Ceftriaxone is not metabolized systemically but is broken down into inactive metabolites by the gut flora. The drug is eliminated by the kidneys (approximately 50–60% excreted unchanged) and the bile (approximately 40–50% excreted unchanged).

---

Q: Is Цефтриаксон ДС (Ceftriaxone) used for treating infections in immunocompromised patients (neutropenia)?

The official therapeutic indications state that Ceftriaxone is used for patients with neutropenia (an abnormally low count of certain white blood cells) who have a fever when a bacterial infection is suspected.

Storage and Disposal Conditions for Ceftriaxone

The sterile Ceftriaxone powder must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), and must be protected from light until it is reconstituted. The container should be kept tightly closed to maintain product integrity. All medication must be stored out of the sight and reach of children.

Stability After Preparation

Stability rules for the prepared solution are time- and temperature-dependent. For example, the reconstituted solution may be stable for 6 hours at 25 C or for 24 hours when refrigerated (2 C to 8 C). Thawed solutions must not be refrozen. Any solution showing visible particulate matter must be discarded.

Official Disposal Rules

Disposal of unused or expired product must follow local, state, and federal requirements. This medicine must not be disposed of via wastewater or household waste.